Our board of directors
We value the support from our investors and the ongoing guidance of our experienced board members.
Johan de Ruiter
Chairman
Johan is Chairman of Quanta Dialysis Technologies and former Executive Vice President, Dialysis International at Fresenius AG.
Previously, Johan initiated and founded Fresenius Medical Care AG, with an IPO on the Frankfurt and New York Stock Exchanges after a $4.5B acquisition. Previously he held executive positions with Baxter Healthcare and Abbott Diagnostics. Johan is also Founder of Auxilium Group and LabNet (which was acquired by Amedes Holding GmbH). He is currently a member of btov and is Chairman and board member of CHT Beitlich/BEZEMA Group as well as being Non-Executive Director to several medtech companies. Johan studied at Nyenrode Business University in the Netherlands and at Michigan State University, USA and has an MBA (Hons) in both Marketing and Finance.
Hooman Hakami
Chief Executive Officer (Interim)
Hooman is Managing Director of Hakami Healthcare Advisors, LCC where he provides advisory services to Boards and CEOs in the healthcare space.
Previously, Hooman was Executive Vice President and President of the Diabetes Group at Medtronic and Company Officer at General Electric. Hooman holds a Bachelor of Business Administration (BBA) from the University of Massachusetts Amherst.
Peter Sandys
Non-Executive Director
Peter is Managing Director of Seroba Life Sciences, was a co-founder of Seroba and has held many directorships in the fund management, technology and financial services industries.
Previously, Peter was Managing Director of ABN Amro Corporate Finance (Ireland) Limited, and has held senior positions with Ernst & Young, 3i venture capital and KPMG. Peter has a BBS degree from TCD and is a Chartered Accountant. He has served twice as Chairman of the Irish Venture Capital Association and was a member of the Irish Stock Exchange’s New Issues Committee and the committee of the Irish Bio Industries Association. He was also formerly a member of the Securities Institute, a Registered Stockbroker and a member of the Institute of Taxation in Ireland.
Rainer Strohmenger
Non-Executive Director
Rainer is Managing Partner of Wellington Partners and is one of Europe’s most experienced venture capitalists in Life Sciences.
With over 23 years’ of investment activity, he has been involved in some of the most successful European biotech, medtech, diagnostics and digital health companies. Previously, Rainer was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, Germany. Rainer holds a M.D. in medicine as well as a M.S.c in economics, both from Ludwig-Maximilians University in Munich, Germany and was trained at the Entrepreneurship Center of the MIT, Boston, USA.
Christian Schütz
Non-Executive Director
Christian is a Partner of btov and a member of the Board of Directors also sitting on the Industrial Technologies Fund Team.
Christian focuses on investments in health data, homecare and other health 4.0 technologies. Christian joined btov in 2003 and shared the responsibility for the private investor network, the set-up of the first two btov funds and all btov portfolio investments in the healthcare and resource efficiency sector. Christian earned a PHD in business administration with a focus on venture capital.
Lee Hathaway
Non-Executive Director
Lee is Partner and Co-Head of Healthcare at Glenview Capital Management where he focuses on healthcare services and medical technology investments.
Previously, Lee worked at Water Street Healthcare Partners, a private equity firm focused exclusively on the healthcare industry and for the Global Healthcare Team within the Investment Banking Division of Barclays Capital. Lee holds a B.A. in both economics and history from Duke University in addition to completing the Markets and Management Certificate Program.
Robert Ghenchev
Non-Executive Director
Robert is Senior Partner and Head of Novo Growth. Previously, Robert was Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the Healthcare Industry.
Prior to Moelis, Robert was part of the UK Mergers & Acquisitions Team at Deutsche Bank in London. Robert holds a J.Hons B.A. in Finance and Economics from McGill University and a M.S.c in Financial Economics from the University of Oxford.
Meghan FitzGerald
Non-Executive Director
Meghan FitzGerald is a global healthcare strategist, investor, academic and author. A highly-regarded expert, she has worked in every domain of healthcare—from front line patient care through the Fortune 500—while serving as an adjunct professor at Columbia University
Currently, Ms. FitzGerald is a private equity investor where she serves as an advisor to several firms, including Goldman Sachs and Wellspring Capital. Prior, Ms. FitzGerald was the chief executive officer and managing partner at Letter One’s inaugural health vehicle, where she allocated approximately $4 billion in three years within pharmaceutical services and animal health. Ms. FitzGerald has spent nearly twenty years as an operator and strategist, working for many prominent healthcare firms, including Merck, Pfizer and Medco. She was also the executive vice president of strategy, mergers and acquisitions and health policy at Cardinal Health and a member of the executive committee. In addition to her board appointment at QUANTA, Ms. FitzGerald is a member of the board of directors at Tenet Healthcare.
Leslie Norwalk
Non-Executive Director
Leslie Norwalk is strategic counsel to Epstein Becker Green, P.C., EBG Advisors and National Health Advisors. She serves as an advisor to several private equity firms and, in addition to QUANTA, sits on the Boards of Directors of Neurocrine Biosciences, Arvinas, NuVasive, ModivCare, Magellan Health, and several privately held health care companies.
In her prior role with the Bush Administration, Ms. Norwalk was acting administrator for the Centers for Medicare & Medicaid Services (CMS), where she managed the day-to-day operations of CMS, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. In addition, Ms. Norwalk was the agency's deputy administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit.
